Business
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025.
About this update from Kyowa Kirin Co., Ltd.
[{"type":"text","content":"PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025.","length":455,"tagName":"p"},{"type":"image","alt":"Kyowa Kirin","displaySize":"","headline":null,"caption":"Kyowa Kirin","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":85,"url":"https://media.zenfs.com/en/prnewswire.com/457f2c3b567b10026bdafdd702399eec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dB7rurJmcnAeqzuNsbPCGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/457f2c3b567b10026bdafdd702399eec","width":400,"height":85}}},{"type":"text","content":"AD, a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus, and pain, is driven by skin barrier disruption and T-cell-dependent inflammatory pathways. Expansion of OX40R+ pathogenic T cells leads to T-cell imbalance, a root cause of inflammatory diseases including AD.","length":370,"tagName":"p"},{"type":"text","content":"Title: Efficacy & Safety of OX-40 Receptor Targeting with Rocatinlimab in Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET-IGNITE Trial ","length":160,"tagName":"p"},{"type":"text","content":"Presenter: Emma Guttman-Yassky, MD, PhD","length":59,"tagName":"p"},{"type":"text","content":"Date: Friday, September 19thTime: 4:40 – 4:50 pm CESTSession: FC 08 Atopic DermatitisLocation: Paris Convention Centre, Pavillon 7.3, Room W05-W06","length":169,"tagName":"p"},{"type":"text","content":"About the ROCKET Phase 3 ProgramROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) as well as multiple dosing regimens.","length":304,"tagName":"p"},{"type":"text","content":"About Moderate to Severe Ato...